Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s00280-020-04168-z.pdf
Reference40 articles.
1. Scott LC, Mobley LR, Kuo TM, Il’yasova D (2019) Update on triple-negative breast cancer disparities for the United States: a population-based study from the United States Cancer Statistics database, 2010 through 2014. Cancer 125(19):3412–3417. https://doi.org/10.1002/cncr.32207
2. Ziaeemehr A, Shahidsales S, Ghosi Z, Avan A, Aldavood AS, Anvari K, Makhdoomi Y, Asadi M (2019) Association of the involvement of axillary lymph nodes in HER-2/neu overexpression in patients with breast cancer. Breast J 25(3):537–538. https://doi.org/10.1111/tbj.13282
3. Giannone G, Milani A, Geuna E, Galizia D, Biello F, Montemurro F (2019) What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer? Expert Opin Pharmacother 20(1):5–9. https://doi.org/10.1080/14656566.2018.1543406
4. Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP (2019) Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 37(22):1868–1875. https://doi.org/10.1200/JCO.19.00066
5. Daniels B, Kiely BE, Lord SJ, Houssami N, Lu CY, Ward RL, Pearson SA (2018) Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016). Breast Cancer Res Treat 171(1):151–159. https://doi.org/10.1007/s10549-018-4804-0
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A microfluidic-based chemiluminescence biosensor for sensitive multiplex detection of exosomal microRNAs based on hybridization chain reaction;Talanta;2025-01
2. Personalized treatment using predictive biomarkers in solid organ malignancies: A review;Tumori Journal;2024-08-02
3. The Predictive Value of Blood-Derived Exosomal miRNAs as Biomarkers in Breast Cancer: A Systematic Review;Clinical Breast Cancer;2024-07
4. Drug resistance in breast cancer is based on the mechanism of exocrine non-coding RNA;Discover Oncology;2024-05-01
5. Diagnostic value of circulating miR-155 for breast cancer: a meta-analysis;Frontiers in Oncology;2024-03-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3